Literature DB >> 10643813

Antagonistic effects of [Nphe1]nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese hamster ovary cells stably expressing the recombinant human nociceptin receptor.

Y Hashimoto1, G Caló, R Guerrini, G Smith, D G Lambert.   

Abstract

Nociceptin/orphanin FQ (NC) is the endogenous ligand for the nociceptin receptor (NCR) which is negatively coupled to adenylyl cyclase to inhibit the formation of cAMP. In this study we describe the inhibitory action of the novel NC analogue, [Nphe1]nociceptin(1-13)NH2 on cAMP formation in Chinese hamster ovary cells expressing the human NCR. NC, NC(1-13)NH2, the pseudopeptides [Phe1psi(CH2-NH)Gly2]NC(1-17)NH2 and [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2, the hexapeptide, acetyl-Arg-Tyr-Tyr-Arg-Trp-Lys-NH2 and buprenorphine all produced a concentration dependent inhibition of forskolin stimulated cAMP formation. This inhibition was competitively reversed by [Nphe1]NC(1-13)NH2 with essentially identical pA2 values (6.12-6.48). [Nphe1]NC(1-13)NH2 showed per se a negligible residual agonist activity (alpha < 0.15).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10643813     DOI: 10.1016/s0304-3940(99)00915-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats.

Authors:  J P Redrobe; G Calo; R Guerrini; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin.

Authors:  S Sbrenna; M Marti; M Morari; G Calo'; R Guerrini; L Beani; C Bianchi
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.

Authors:  G Calo'; R Guerrini; R Bigoni; A Rizzi; G Marzola; H Okawa; C Bianchi; D G Lambert; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.

Authors:  J McDonald; G Calo; R Guerrini; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-15       Impact factor: 3.000

6.  Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Authors:  Taline V Khroyan; Willma E Polgar; Faming Jiang; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2009-08-27       Impact factor: 4.030

Review 7.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

Authors:  Nurulain Zaveri
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.